abstract |
Disclosed is the use of an antagonist of a tumor-associated antigenic target 179 (TAT 179) polypeptide of SEQ ID NO:93 in the manufacture of a medicament for inhibiting the growth of a cancer cell expressing said TAT 179 polypeptide, wherein the antagonist is selected from the group consisting of anti-TAT 179 antibodies and functional fragments thereof, functional fragments and variants of native TAT 179 polypeptides, peptides, antisense oligonucleotides, and small organic molecules. |